Quick Answer
Oric Pharmaceuticals, Inc. reported Operating Income Loss of -$143.00 million for the year ending 2025.
- Oric Pharmaceuticals, Inc. showed a decrease of -0.1% in Operating Income Loss from 2024 to 2025.
- This data is from Oric Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$6.35 million | Q2 2019: -$6.36 million | Q3 2019: -$7.10 million | Q1 2020: -$9.18 million | Q2 2020: -$11.12 million | Q3 2020: -$25.60 million | Q1 2021: -$16.55 million | Q2 2021: -$21.06 million | Q3 2021: -$18.46 million | Q1 2022: -$23.26 million | Q2 2022: -$20.70 million | Q3 2022: -$25.69 million | Q1 2023: -$25.68 million | Q2 2023: -$24.99 million | Q3 2023: -$28.68 million | Q1 2024: -$28.99 million | Q2 2024: -$36.02 million | Q3 2024: -$38.32 million | Q1 2025: -$32.72 million | Q2 2025: -$39.06 million | Q3 2025: -$36.67 million.
- Over the full 8 years of available data (2018 to 2025), Oric Pharmaceuticals, Inc.'s Operating Income Loss has declined by 539.2%.
- Historical annual values: Fiscal year 2025: -$143.00 million | Fiscal year 2024: -$142.90 million | Fiscal year 2023: -$110.78 million | Fiscal year 2022: -$91.77 million | Fiscal year 2021: -$78.87 million | Fiscal year 2020: -$74.19 million | Fiscal year 2019: -$28.57 million | Fiscal year 2018: -$22.37 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: